Background: A randomized controlled trial involving a high-risk, unvaccinated population
that was conducted before the Omicron variant emerged found that nirmatrelvir–ritonavir …

Objective To assess the effectiveness of nirmatrelvir-ritonavir in the treatment of outpatients
with mild to moderate COVID-19 who are at higher risk of developing severe illness, through …

Background Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for
COVID-19 treatment, but direct comparisons of their effectiveness have been limited. This …

Background: In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …

Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …

Background Studies have established the short-term efficacy of nirmatrelvir–ritonavir in
managing COVID-19, yet its effect on post-COVID-19 condition, especially in patients …

Background Nirmatrelvir/ritonavir has shown to reduce COVID-19 hospitalization and death
before Omicron, but updated real-world evidence studies are needed. This study aimed to …

At present, there are some differences in the research results of nirmatrelvir–ritonavir
compared with other antiviral drugs for the treatment of COVID‐19 patients. We aimed to …

Background Real-world data is currently limited on the association between oral antiviral
therapy and healthcare system burden in patients with mild-to-moderate COVID-19. This …

Background: In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk
Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death …